Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TCRT

TCRT - Alaunos Therapeutics, Inc. Stock Price, Fair Value and News

$2.80-0.15 (-5.08%)
Market Closed

18/100

TCRT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

18/100

TCRT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.34

Target 3M

$2.64

Target 6M

$2.49

TCRT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TCRT Price Action

Last 7 days

-6.7%

Last 30 days

-18.6%

Last 90 days

4.5%

Trailing 12 Months

68.7%

TCRT RSI Chart

TCRT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TCRT Valuation

Market Cap

6.2M

Price/Earnings (Trailing)

-1.55

Price/Sales (Trailing)

1.0K

Price/Free Cashflow

-2.32

TCRT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.34

Target 3M

$2.64

Target 6M

$2.49

TCRT Fundamentals

TCRT Revenue

Revenue (TTM)

6.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

TCRT Earnings

Earnings (TTM)

-4.0M

Earnings Growth (Yr)

-2.84%

Earnings Growth (Qtr)

-10.28%

TCRT Profitability

Return on Equity

-143.58%

Return on Assets

-108.07%

Free Cashflow Yield

-43.16%

TCRT Investor Care

Shares Dilution (1Y)

39.38%

Diluted EPS (TTM)

-2.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202510.5K6.5K6.0K0
20245.5K6.0K6.5K9.5K
202302.2M1.1M5.0K
2022003.3M3.3M
202100272.0K398.0K
20184.8M3.3M1.7M146.0K
20176.5M6.4M6.4M6.4M
20166.0M7.5M7.2M6.9M
20151.4M1.5M2.8M4.3M
2014800.0K800.0K1.2M1.4M
2013800.0K800.0K800.0K800.0K
2012800.0K800.0K800.0K800.0K
2011000667.0K
20100000
Get all data in R, Python etc through our Historical Stock Data APIs

About Alaunos Therapeutics, Inc.

TCRT
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
 CEO
 WEBSITEalaunos.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES34

Alaunos Therapeutics, Inc. Frequently Asked Questions

TCRT is the stock ticker symbol of Alaunos Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Alaunos Therapeutics, Inc. is 6.25 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check TCRT's fair value in chart for subscribers.

The fair value guage provides a quick view whether TCRT is over valued or under valued. Whether Alaunos Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Alaunos Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TCRT.

As of Wed Jan 28 2026, TCRT's PE ratio (Price to Earnings) is -1.55 and Price to Sales (PS) ratio is 1.04 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TCRT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Alaunos Therapeutics, Inc. has provided -0.428 (multiply by 100 for percentage) rate of return.